Nanwei Medical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nanwei Medical - overview
Established
2000
Location
Nanjing, Jiangsu, China
Primary Industry
Medical Devices & Equipment
About
Established in 2000 and based in Nanjing, China, Nanwei Medical operates as a medical device developer that mainly provides endoscopic minimally invasive diagnostic and therapeutic equipment. It has established wholly-owned subsidiaries in the United States, Germany, Japan, Switzerland, and other places and has more than 10 marketing centres in China. Actis invested USD 17 million in the company in September 2012. In July 2019, Nanwei Medical was listed on the Shanghai Stock Exchange.
The company mainly provides endoscopic minimally invasive diagnostic and therapeutic equipment. Products include endoscopic diagnostic and treatment instruments, microwave ablation equipment and consumables, and disposable endoscopes. Endoscopic diagnostic and treatment instruments include biopsy, hemostasis and closure, and dilation. Microwave ablation equipment and consumables include microwave ablators and microwave ablation needles.
Products can be used in clinical departments such as gastroenterology, respiratory medicine, interventional ultrasound, general surgery, and oncology. The company generates revenue by providing endoscopic minimally invasive diagnostic and therapeutic equipment.
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment, Medical Supplies
Website
www.micro-tech.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Nanwei Medical - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 41,409,708.1 | 640,672,960.1 | 922,109,299.9 | 1,307,474,273.6 | 1,326,405,645.5 | - | - | - |
| % Revenue Growth (YoY) | - | 1447.2% | 43.9% | 41.8% | 1.4% | - | - | - |
| EBITDA (USD) | (5,496,640.8) | 144,152,690.3 | 241,288,969.2 | 371,120,716.8 | 308,645,628.3 | - | - | - |
| Operating Income (USD) | (14,368,740.8) | 131,736,590.3 | 225,685,298 | 351,523,513.4 | 282,229,470.1 | - | - | - |
| Operating Margin | (34.7%) | 20.6% | 24.5% | 26.9% | 21.3% | - | - | - |
| % EBITDA Margin | (13.3%) | 22.5% | 26.2% | 28.4% | 23.3% | - | - | - |
| NET Income (USD) | (26,033,457.9) | 112,148,510.4 | 203,393,539.3 | 315,152,622.2 | 266,136,462.5 | - | - | - |
| % Net Margin | (62.9%) | 17.5% | 22.1% | 24.1% | 20.1% | - | - | - |
Nanwei Medical - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Nanwei Medical | - | ||||||||
| Secondary Buyout | Completed | Nanwei Medical | - | ||||||||
| Growth | Completed | Nanwei Medical | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.